Healthcare >> CEO Interviews >> December 2, 1999
COLIN GODDARD was appointed Chairman of the Board in August 2000 and
Chief Executive Officer of OSI Pharmaceuticals, Inc., in October 1998.
He served as President from September 1997 to September 2000; Executive
Vice President and Chief Operating Officer from September 1996 to
September 1997; Vice President, Research Operations, from December 1993
to September 1996; Director, Drug Discovery, from April 1992 to April
1993; and Program Manager, Drug Discovery, from April 1991 to April
1992. Dr. Goddard joined the corporation as a scientist in January 1989.
Dr. Goddard was also elected Chairman of the New York Biotechnology
Association in January 2001. Dr. Goddard was instrumental in the
transition of OSI from a high throughput screening/technology
platform/service-based organization with a modest market cap and limited
cash reserves to the fully integrated drug discovery organization it is
today, well positioned and well financed for continued future growth.
The transition has been accomplished through acquisitions (Aston
Molecules (1996), MYCOsearch (1996), Cadus (1999)), the divestiture of
the company's diagnostics unit, and public and private financing efforts
and corporate deals raising over $525 million. In the early 1990s, Dr.
Goddard was responsible for the development of the corporation's
pioneering robotic high throughput screening operation. Before joining
the corporation, Dr. Goddard spent four years at the National Cancer
Institute in Bethesda, Maryland. Dr. Goddard trained as a cancer
pharmacologist in Birmingham, UK, receiving his PhD from the University
of Aston, Birmingham, UK, in 1985. Profile
Dr. Goddard: OSI was formed in the mid 1980s, to exploit the then
emerging field of oncogenes for therapeutic and diagnostic
